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Transfusion of one unit or more of Rh-positive red 
blood cells normally causes circulating anti-D antibody 
to a.,!>pear 2-6 months later in 80-95% of Rh- persons. 
We asked whether transplant immunosuppression with 
cyc1osporine and corticostel'oids affects Rh immuniza-
tion. Nin?t~n Rh- Ii.ver, heart, and heart-lung trans-
plant recipients receIved 3-153 (median: 10) units 'Of 
Rh+ RBCs at surgery and were tested for anti-D >2 
months later. Three patients developed anti-D at 11-15 
days; one may have had an unusually rapid primary 
immune response and two were-secondary to previous 
exposure by pregnancy. None of the other 16 patients 
bad anti-D when tested 2.5-51 months later (13 pa-
tients, > 11.6 months). This low rate of Rhesus immuni-
zation in association with cyclosporine immunosuppres-
sion allows greater flexibility in meeting the transfusion 
needs ofRh-liver and heart transplant patients. Caution 
is stilI advised in young females and in patients who 
may ha~e been previously exposed to Rh+ RBCs by 
transfusJOn or by pregnancy prior to the availability of 
perinatal.Rh immune globulin twenty years ~go. Other 
humoral Immune responses_to some vaccines or infec-
tious agents may also be impaired in transplant patients. 
The D antigen on red blood cells is highly immunogenic. As 
little as 30 "I of RBCs has caused Rh immunization, and after 
a single I-m.l injection of Rh-+ RBCs, 10-40% of Rh- subjects 
develop antI-D (1). After transfusions of one or more Rh+ 
units, anti-D appears 2-6 months later in 80-95% of Rh-
persons (2-4), Hemolytic disease of the newborn (HDN)' or 
hemolysis of Rh-incompatible RBC transfusions may then 
ensue. 
Transplantation of livers, hearts, and heart-lungs can require 
large amounts of blood (5, 6). Because only 15% of white and 
7% of black patien~s are Rh-, sufficient Rh- blood may not 
always be available for Rh- patients. In yiew of the setting of 
transplant immunosuppression, we studied our Rh- organ 
transplant recipients who received Rh· RBCs during surgery 
to determine whether they subsequently formed anti-D at th~ 
normal high rate. ThE' -results are of interest with regard to 
both transplant transfusion management and the pathogenesis 
of Rhesus immunization. 
MATERIALS AND METHODS 
Standard serologic methods (7) were employed in Central Blood 
Bank's transfusion service at the University of Pittsburgh, which-
supports adult organ transplants at Presbyterian-University Hospital 
and pediatric transplants at Children's Hospital of Pittsburgh. Blood -
bank records were reviewed for Rh-Jjver, heart, and heart-lung trans-
plant patients from 1981 to early 1987, and all who received Rh + RBCs 
Ouring surgery were assessed in retrospect for evidence of subsequent 
anti-D. None ofthese patients had anti-D at our center prior to surgery. 
We then BOught new samples from survivors for RBC antibody testing, 
including use of ficin·treated screening RBCs to enhance reactivity of 
Rh antibodies. We also reviewed,a second group of patients with anti-
D prior to surgery in order to assess thp subspquent persistence of 
antibody. As is customary, we tested blood donors, but not patients, 
for the weak Rh+ DU phenotype present in 0.23--0.56% of all people (I), 
or about 1.5-3% of apparently Rh- patients. 
For immunosuppression, our transplant programs have e1npl~yed 
cyclosporine, corticosteroids, adjunetive rabbit antiTymphocyte globu-
lin, and-in recent years-OKT3 monoclonal antibody (8-12). 
RESULTS 
The proportions of Rh- transplant patients recei\'ing intra-
operative Rh~ RBCs because of rapid need and/or low Rh-
inventory were as follows: liver, 19 of 109; heart, 8 of 51; and 
heart-lung, 2 of 8. None received Rh immune globulin (RhIG). 
Eight of the 29 patients given RhO< RBCs died within 2 
months; three of these 8 had no anti-D by 7 weeks. Two other 
patients were not tested for RBC antibodies bevond one month -
after surgery. Thus, a total of 19 patients had ~ufficient follow· 
up for analysis. 
Three liver transplant patients developed anti-D 11-15 days 
after receiving Rh+ RBCs. Two were women 64 and 53 years 
old, each with 3 past pregnancies and thus presumablv imm\!-
nized prior to the licensure of perinatal RhlG in the U.S.A. in 
1968. One received 29 Rh'; units during two liver transplants 
over 12 days. Three days later, anti-D was present in the serum 
and on circulating RBCs; concurrently, the hematocrit dropped 
from 34% to 26%, and the total and indirect bilirubin levels 
rose from 8.1 and 3.4 mg/d! to 19.0 and 8.6 mgldl. The other 
woman received 3 Rh'; units. the last of 13 in total. Anti-D 
appeared in the serum, but not on circulating RBCs, at 11 days, 
. 'Addres~ correspondence to: Glenn Ramsey, M.D., Central Blood along with a hematocrit change from 28t;( to 18t;( and a rise.in 
Bank, 812 Fifth Avenue, Pittsburgh. PA 15219. - total and inilirect bilirubin from 8.9 and 3.; mg/d) to 20 and 
• Central Blood Bank. 6.2 rug/d!. Thus, both of these patients had evidencE' of mild 
3 Department of Pathology. delayed hemolysis at times when no bleeding was apparent. 
• Department of Surgery. The third patient was a 61-year-old man who was never 
.• Abbrpviations: HDN. hi>molytir dispase ofth~ npwhorn: RhIG. Rh known to have received Rh.; RBCs or platelet.." and had no 
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After transfusion of 10 units of Rh" RBCs, anti-D and -E were 
found in the serum, but not on RBCs, at 11 days, but were 
undetectable at another hospital two months after surgery. 
There were no RBC antibodies found in the plasma of his blood 
donors. The organ donor was Rh.., virtually ruling out the graft 
as the origin of the anti·D. Evaluation-for hemolysis was 
obscured by concurrent reoperation for biliary obstruction. 
Of the other 16 patients, none had_ anti-D ~2 months later, 
including 13 with followup ~1l.5 months (Table 1). Two were 
female patients 41 and 53 years old; the rest were male. 
Two of these patients were later given Rh + RBCs again, but 
died shortly thereafter. Case 1 received such units a few days 
before death, and case 16 was given more than 50 more Rh+ 
units during his 2.5-month survival period. 
Four other liver transplant patients with preoperative anti-
D had::!: 1 month of follow-up antibody testing after surgery. In 
each case the anti-D was still detectable 1.5, 18, 48, and 52 
months later. This suggested that immunosuppression did not 
interfere with the us~al long-term persistence of preexisting 
anti·D (7). -
DISCUSSION 
In a previous retrospective blood bank study of 1000 consec· 
utive liver transplants in 781 patients at our center (13), many 
RBC antibodies appeared 1-5 weeks later, but only 3 patients 
were found Wilave formed new significant RBC alloantibodies 
(anti-K and -E) after more extended follow-up (from 7 weeks 
to 4.5 months). However, the true rate of primary RBC alloim-
munization was uncertain because most patients did not have 
long-term testing. In this study of 19 Rh- organ transplant 
patients tested >2 months after receiving numerous Rh+ RBCs, 
there was only one apparently primary anti-D, there were two 
rapid secondary immune responses, and in 16 patients no 
subsequent antibody wa& found. Lack of alloimmurllzation was 
further suppo_rted by negative results of additional testing in 
10 patients when enzyme-treated screening cells were used to 
enhance Rh antibody detection. 
In immunocompetent subjects receiving::!:l Rh-incompatible 
TABLE 1. Rh- transplant patients testing negative for anti-D l!!2 
months after receiving Rh~ RBCs at surgery 
Case Age Sex Organ lJnits of Times of testin!: Rh+ RBCs (month.) 
1 33 M Liver 5 3,51· 
2 5 M Liver 10 45' 
3 56 M Heart 4 5,31· 
4 43 1.1 Heart-lung 6 24' 
[, 9 1.1 Liver 16 5,24' 
6 33 M Heart 7 5,22' 
7 43 1\1 Heart 6 21 b 
8 53 F Liver 12 3,20' 
9 61 M Liver 10 20· 
w- 53 M Heart ~ 20 I 
11 41 F Liver 7 5,12, 19' 
12 43 M Liver 14 12' 
13 22 1\1 Heart 19 3,6, 11.5" 
14 32 1\1 Liver 15:, 3D 
15 23 1\1 Liver 138 2.5 
16 29 M Liver 86 2.[,D 
Median: 10 20 (longest) 
"Died. 
• EnzymE'-treated RBC's used in final antibody testing. 
unit of RBCs, RO-95<;( formE'd anti-D. Cook and Rush (:1) 
tested 20 heart surgery patients who had received 12-33 uni16 
of RBCs; 19 (95%) had anti-D, although 7 antibodies Yt'ert 
detected only by enzyme·treat~d test cells. After 500 ani of 
whole blood, 18 of 22 subjects (82%) studied by Pollack et aI. 
(2) were alloimmunized, without any detection advantage in 
enzyme screening (14). Likewise, Urbaniak and Robertson (4) 
found thar24 of 28 subjects (8fi%) formed a!1ti-D after 200 IIl1 
of RBCs. RhIG has prevented Rh immunization after Up to 
1000 ml of RBCs, but the dose required is massive-6.7 rnl/lOO 
ml RBCs, which in the U.S. must be given intramuBCWarly_ 
and may cause symptomatic hemolysis of the Rh + RBCa (J 
15). Anti-D generally does not appear until 2-6 months afte; 
exposure. In the 18 subjects tested monthly by Pollack et aI_ 
(2), antibody first appeared in 9 at 2 months, in 7 at 3 montlu; 
and in 2 at 4-5 months. Furthermore, anti·D is generally ~er; 
persistent. We previously found that 86% of such antibodies 
were still present 1-60 months after detection (7). Therefol't.. 
anti-D would have been expected in most of Qur patients. 
Our lone case ofprilllary anti-D formation is similar in timing 
and transience to a case of anti·D after liver transplant ob. 
served by Blomqvist et al. (16). After 38 units of Rh+ blood, 
this antibody was detected by enzyme-treated RBCs at day~ 
12-16 and subsequently disappeared in a previously untraru-
fused male patient (Blomqvist BI, personal communication). 
However, the most r,apid primary anti·D response previously 
reported was at 4 weeks (J). It is also possible that these two 
patients had previously undetected levels of "naturally 0CCUl-
ring" anti-D; some of these antibodies can be stimulated h) 
exposure (17, 1 B). 
Our findings are of praetical importance for transfusion 
management ofRh- organ transplant patients when Rh- blood 
is in short supply. Excluding our two-secondary immune re-
sponses, the frequency of subsequently detectable primary anti-
D was low 0/17) after multiple Rh' RBCs. Perhaps immuno-
suppressive regimens could be devised for other settings oflargt-
Rh-incompatible blood exposure. However, two cautions should 
be made. First, in transplant patients who may have been 
previously Rh-sensitized by transfusions or remote pregnan-
cies, delayed hemolytic transfusion reactions can ensue after 
Rh" RBC transfusions, as -noted here and as we and othel'!' 
have observed with non-D RBC antibodies (IS, 19). Second. 
only two of our patients have been rechallenged with Rh+ 
RBCs, and they died shortly thereafter. In the pre-RhJG era, 
SOl!le women sensitized by low levels of Rh" f~tal RBCs did not 
produce anti-D until the next Rh+ gestation. Therefore, it i!; 
possible that some of our patiellts have been silent~ immu-
nized. None were girls or women of childbearinE age (Table 1). 
SincE' successful pregnancies have occurred after cyclosporine 
transplantation (20), we still recommend avoidance of Rh" 
RBCs in -girls or young women, if feasible~ pending further 
data. -
In the setting of cancer therapy immunosuppression, re-
peated Rl}-incompatible platelet and granulocyte transfusiom 
containing small amounts. of Rh" RBCs have led to varyin!: 
rates of anti-D formation. Two studies yielded 8-1BSC rates of 
Rh alloimmunization (21,22), but another group reported only 
a 2% frequency (23). Our RBC datB suggest that the risk of 
immunization by Rh" platelets alone would be minimal in liver 
and heart transplantation. 
Rh" RBC" in kidney grafts occasionally have ('lmsed primar), 
or secondary alloimmunization in Rh- transplant recipient;; 
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(2-1): h0\\'E'\'er, !,E'vera] of thE'!'e instances wen' associatpd with 
r-aft rejection, suggesting that immunosupprpssion might haw 
been insufficient. In bonE' marrow transplantation, Rh- recip· 
ients of Rh- grafts seldom form anti-D, although Rh- grafts 
~ornptimes do so to an Rh- host or transfused RBCs (25, 26). 
Our results in RBC transfusions may be related to experi-
mental evidence in rats and dogs that cyclosporine can prevent 
transfusion-induced humoral alloimmunization to antigens of 
the major histocompatibility complex (27,28). In humans, this 
drug has been reported to impair T cell-dependent antibody 
",sponses in bone marrow transplant recipients immunized 
" .. ith keyhole limpet hemocyanin (29), and also in renal trans-
plant patient-s who were given influenza vaccine (30). Further 
,...ork to determine whether the RBC Rh protein might also be 
8 T cell-dependent antigen would be of interest. Besides cyclo· 
5porine, the other immunosuppressive measures employed in 
our patients could have played a role in the effect we observed. 
Primary antibody responses to other antigens such as vaccines 
or infectious-agents may also be impaired at the time of organ 
tra;splantation. 
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